contribute to abnormal splicing and stabilization of certain factors, which can eventually help in disease progression.
To further investigate the mechanism of PTBP2 repression by miR-223, we targeted the PTBP2 (m) 3 0 UTR downstream of a luciferase reporter gene with miR-223 ( Figure 2e ). In 293T cells, miR-223 was able to reduce luciferase activity by 68%, indicating that this miRNA may directly target the PTBP2 3 0 UTR ( Figure 2f , first and second bar). This reduction was abolished by a 3 0 UTR that contains specific mutations in the seed region (from 5 0 -UUUCUAAAACUGA-CAA-3 0 to 5 0 -UUUCUAAAACACUCAA-3 0 ) of the miR-223 target sequence, indicating that miR-223 can directly influence PTBP2 protein level through specific binding to its 3 0 UTR (Figure 2f , third and fourth bar). The above data support that PTBP2 is a direct target of miR-223 and it acts through the 8 0 mer conserved binding site, which is present in the PTBP2 3 0 UTR. This target site is well conserved in other vertebrates, suggesting that miR-223 may control PTBP2 levels in wide range of organisms and diseases.
A connection between miRNAs and hematopoiesis was made when it was demonstrated that certain miRNAs are expressed within specific hematopoietic lineages, and their expression levels regulate hematopoietic differentiation. 14 In this study, we report that miR-223 downregulation affects the transcription factor MEF2C and alternative splicing factor PTBP2. It has been long recognized that alternative splicing can generate numerous protein isoforms, at times with variant function, which are encoded by the same pre-RNA transcript. BCR-ABL dependent increase in expression of multiple genes involved in pre-mRNA splicing is already reported (for example, SRPK1, RNA helicase II/Gsi and hnRNP A2/B1). 15 Taken together, these results suggest that changes in the miR-223/PTBP2 pathway could contribute to the abnormal splicing of several genes and shed light into the potential role exerted by miRNAs in a subset of CML. Not only did it highlight the ability of miRNAs to alter mRNA but also, more importantly, it added a new layer to the complexity of mechanisms regulating the phenotype of CML.
Decitabine facilitates the generation and immunosuppressive function of regulatory gdT cells derived from human peripheral blood mononuclear cells Leukemia (2013) 85  80  75  70  65  60  55  50  45  40  35 Letters to the Editor homeostasis 3 and immunoregulation. 4 The diverse functions emphasize the plasticity and heterogeneity of gdT cells to influence the nature of immune response. gdT cells in different microenvironments can assume features reminiscent of classical Th1, Th2, Th17 and regulatory T cells, as well as professional antigen-presenting cells. 5 Regulatory gdT cells (gdTregs) have been detected in lymphocytes infiltrating breast tumors, and in renal and skin allografts, 4, 6, 7 although their detailed immunological features have not been well investigated, largely because of the lack of appropriate strategies for population expansion. Protocols for gdT cell induction and expansion have been developed by several groups, and several recent studies have focused on gdTreg identification, induction and function. Rita et al. 8 reported that gdTregs, characterized by the presence of TCRgd and a high level of forkhead/winged-helix family transcriptional repressor p3 (Foxp3) expression, existed at low but significant frequencies in humans, and could be generated in vitro from human peripheral blood mononuclear cells (hPBMCs) with immunosuppressive function. Foxp3-positive cells were also implicated in the pathogenesis of systemic lupus erythematosus. 9 Thus, we hypothesized that gdTregs could be explored as an adoptive immunotherapy against graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
To this end, a large-scale, efficient expansion of gdTregs represents a fundamental prerequisite. DNA hypomethylating agents including 5-aza-2 0 -deoxycytidine and decitabine are reported to act synergistically with transforming growth factor (TGF)-b1, interleukin (IL)-2 and TCR stimulation to convert a variety of naive T cells to induced abTregs (iTregs). 10 DNA hypomethylating agents have also been reported to mitigate GVHD without sacrificing graft-versus-leukemia (GVL) effect by inducing the conversion of CD4 þ CD25 À effector T cells to CD4 þ FOXP3 þ Tregs. 11 In an effort to know the effect of decitabine on the induction of gdTregs, hPBMCs from healthy volunteers were cultured in the presence of zoledronic acid (ZOL)/ cytokines or combinations of ZOL/cytokines plus decitabine as indicated. On day 10, frequencies and absolute numbers of Foxp3 þ TCRgd þ gdTregs were evaluated. Details of materials and methods can be found in the Supplementary Information. As a result, gdTregs were significantly increased in all hPBMCs cultured with or without decitabine, compared with freshly isolated hPBMCs ( Figure 1a) . We also found a parallel considerable increase in non-gdFoxp3 þ Tregs in accordance with previous reports. 10, 11 The frequency and absolute number of gdTregs differed depending on the media additives ( Figure 1b) . A higher frequency of gdTregs was detected in cells treated with decitabine plus ZOL/IL-2/IL-15/TGF-b1 (referred to as decitabine-induced gdTregs below). Decitabine at 0.5 mmol/l induced the highest frequency and absolute number of gdTregs (Po0.05) (Supplementary Figure 1) . Moreover, the mean fluorescence intensity of Foxp3 in decitabine-induced gdTregs was higher than in gdTregs without decitabine induction (referred to as common gdTregs) (Supplementary Figure 2 , Po0.05). Therefore, 0.5 mmol/l decitabine was considered as an optimal concentration to be applied in following experiments.
In addition, this finding encouraged us to investigate the influences of decitabine on biological features of gdTregs. We enriched gdTregs by positive selection of TCRgd þ cells using magnetic bead sorting (MACS) purification. Among these TCRgd þ cells, an average of 55-65% were gdTCR þ Foxp3 þ in decitabineinduced group. In contrast, 30-40% were TCRgd þ Foxp3 þ in groups without decitabine induction. We subsequently evaluated the immunosuppressive function of the enriched gdTreg populations on carboxyfluorescein diacetate (CFSE)-labeled hPBMC proliferation in vitro. As shown in Figure 1c and Supplementary  Figure 3 , both common gdTregs and decitabine-induced gdTregs exerted dose-dependent suppression on proliferation, whereas decitabine-induced gdTregs had a statistically higher suppressive potency than common gdTregs (Po0.05). Supernatant cytokine measurements demonstrated that interferon-g and tumor necrosis factor-a production by anti-CD3/anti-CD28-stimulated T cells were more severely inhibited by decitabine-induced gdTregs than by common gdTregs in dose-dependent manners, and were not inhibited by gdT cells (Supplementary Figure 4) . Expression levels of activation-related molecules including human leukocyte antigen (HLA)-DR, CD69, cell origin markers CD45RA and CD45RO, as well as Treg-related markers including CD127, ICOS, CD25, CTLA-4 
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Letters to the Editor and GITR were measured and compared in both populations. As shown in Figure 1d , HLA-DR and ICOS were obviously upregulated in decitabine-induced gdTregs. These results implied that decitabine-induced gdTregs were highly activated with upregulated expression of the immunosuppressive marker ICOS. The abTreg lineage has recently been described to be capable of reverting to an effector phenotype both in vivo and in vitro. 12 We therefore compared the stabilities of the two induced gdTreg populations. Enriched common gdTregs and decitabine-induced gdTregs were cultured with IL-2, IL-15 and with or without TGF-b1 for 5 days. Less than 3% of decitabine-conditioned gdTregs and 10-20% common gdTregs reverted in TGF-b1-free medium, compared with those in TGF-b1-containing medium (Supplementary Figure 5) . These results suggested that decitabine-induced gdTregs had improved stability in vitro. Collectively, these results showed decitabine-induced gdTregs were highly activated and showed improved immunosuppressive functions and stability in vitro.
Next, we tried to investigate mechanisms responsible for the enhanced suppressive activity of decitabine-induced gdTregs. By CFSE-based suppression assay, we detected levels of TGF-b1, IL-4 and IL-10, known as inhibitory cytokines involved in T lymphocyte suppression. As shown in Figure 1e , the levels of TGF-b1 and IL-10 in culture supernatants of decitabine-induced gdTregs were higher than in supernatants from common gdTregs (Po0.05), although both gdTreg populations produced high levels of TGF-b1 and IL-10. As shown in Figure 1f , suppression of both gdTreg populations was partially restored by addition of anti-TGF-b1 monoclonal antibody, anti-IL-10 monoclonal antibody, or both, at high concentrations, albeit the suppression rates differed significantly between the two populations. These results indicated that enhanced production of TGF-b1 and IL-10 by decitabineinduced gdTregs facilitated their suppressive functions.
Finally, we compared the in vivo safety and potency of common gdTregs and decitabine-induced gdTregs. Phytohemagglutininactivated autologous hPBMCs containing 1 Â 10 7 T cells on day 0 were initially transplanted. Different types of expanded and enriched gdT cells were adoptively transferred (gdTregs:hPBMCs at a ratio of 1:1) on day 7 to help stratify potential differences in outcome (Figure 2a) . hPBMC engraftment was confirmed by flow cytometry, with 70-85%, 80-92% and 15-25% of cells in the peripheral blood, bone marrow and spleen, respectively, being human CD3 þ by day 14 after hPBMC adoptive transfer. The majority (80-90%) of these cells were CD8 þ T cells (Figure 2b) . As a result, lethal GVHD was induced in mice in control group and gdT cell groups, with average survival times of 18.2±2.3 and 18.0 ± 2.6 days, respectively. In contrast, the average survival times were 32.0 ± 2.2 and 45.5 ± 4.3 days in the common gdTreg group and decitabine-induced gdTreg groups, respectively (Figure 2c) . To investigate the infiltration of human lymphocytes into nonlymphoid tissues in xenogeneic GVHD-induced mice, we performed immunohistochemical analysis of the liver, lungs, intestines and kidneys from the four groups using an anti-human CD45 monoclonal antibody. On day 14 after adoptive transfer of different kinds of gdT cells, abundant invasion of human CD45 þ cells was observed around the veins in liver, lungs, intestines and kidneys of mice of the control and gdT cell groups, whereas less invasion was seen in the common gdTreg group, and least invasion in the decitabine-induced gdTreg group (Figure 2d) . These results indicated that decitabine-induced gdTregs maintained potent immunosuppressive functions against GVHD in vivo.
In conclusion, we found that decitabine facilitated the generation of gdTregs and decitabine-induced gdTregs displayed enhanced immunosuppressive functions in vitro and in vivo. Further analysis revealed that inhibitory molecules Foxp3 and ICOS were upregulated obviously, as well as inhibitory cytokines TGF-b1 and IL-10 production. Foxp3 expression became more stable in decitabine-induced gdTregs, which might be synergistically responsible for their enhanced immunosuppressive function.
In addition, our data showed that HLA-DR was upregulated in decitabine-induced gdTregs. HLA-DR þ abTregs were reported to express higher levels of Foxp3 and induced a more intense and rapid T-cell suppression than abTregs lacking HLA-DR expression. HLA-DR upregulation in decitabine-induced gdTregs might also contribute to the enhanced immunosuppressive functions.
Currently, GVHD is still a common cause of death after allo-HSCT. Novel modalities including new monoclonal antibodies, cellular therapies and photochemotherapy were applied in clinical trials and achieved certain efficacy. 13, 14 There is still no satisfying treatment for refractory GVHD. The cytotherapy using CD4 þ CD25 þ Tregs has been severely hampered by their low frequency, unfavorable ex vivo expansion properties and ease of contamination with effector T cells after isolation. 15 In our study, enriched inhibitory gdTregs effectively alleviated GVHD in vivo implied a potential gdTreg-based immunotherapy.
This study demonstrated for the first time that decitabine combined with IL-15/IL-2/TGF-b1/ZOL could facilitate the induction and immunosuppressive functions of gdTregs derived from hPBMCs in vitro and in vivo. Juvenile myelomonocytic leukemia (JMML) is a rare leukemia of infancy and early childhood. A hallmark of JMML is that JMML cells are selectively hypersensitive to GM-CSF in vitro, but have normal sensitivity to IL-3, which shares the b-subunit receptor with GM-CSF. 1, 2 The pathogenesis of JMML is linked to dysregulated signal transduction through the Ras signaling pathway caused by mutations of RAS, PTPN11 and c-CBL, or loss-of-heterozygosity of NF1. 3, 4 Although most patients with JMML experience an aggressive disease course, some others spontaneously resolve. 3, 5 No specific mutation has been definitively demonstrated to confer a poorer prognosis, with the exception of perhaps PTPN11, which has been shown to be associated with a higher risk of relapse in some series. In addition, gene expression and methylation analyses have identified signatures associated with outcome that are unexpectedly independent of genotype, 5, 6 leading us to believe that additional mutations or events mitigate the course of JMML. Finally, the mechanisms that underlie selective GM-CSF hypersensitivity are not well established in JMML.
We previously reported that constitutively-hyperactive MAPK and Akt were found in 73% and 55% of JMML patients, respectively, and that a tumor suppressor, PTEN (phosphatase and tensin homolog deleted on chromosome ten), was deficient in 67% of JMML patients. 7 As PTEN functions as an antagonist to MAPK and PI3K/Akt activities, 7 its deficiency in JMML might therefore result in an inability to antagonize the over-activity demonstrated by GM-CSF hypersensitivity. However, PTEN has never been linked to GM-CSF signaling specifically. Therefore, in this study, we sought to identify additional molecules that specifically affect GM-CSF signaling in JMML. One such possible protein is CREB (cAMP-response-element-binding protein), which is a member of the activating transcription factor family. The phosphorylation status of CREB determines whether it acts on the c-Jun promoter in a repressive or activating manner to affect c-Jun gene transcription. 8 c-Jun has been found to be overexpressed in JMML, which is a coactivator of PU.1 in promoting monocytic differentiation. 9 CREB has also been described as a protooncogene, overexpressed in 65% of acute myeloid leukemia (AML), and is related to growth dynamics for colony-forming unit/ granulocyte macrophage (CFU-GM). 10 In order to test our hypothesis that there might be a CREBrelated aberrancy in JMML, we collected peripheral blood (PB) or bone marrow (BM) from 47 JMML patients at diagnosis, and evaluated CREB protein levels in mononuclear cells (MNCs) from 26 of these who had sufficient sample material for western blot. In contrast to the data reported in AML, we found that 22/26 (85%) of subjects had substantially lower CREB protein levels than normal controls (Figure 1a) . In further quantifying the total CREB protein using ELISA, we found that the median level of CREB protein was significantly lower in JMML subjects (0.62 ng/mg BSA, n ¼ 26) as compared with 7 normal controls (8.8 ng/mg BSA, P ¼ 0.006; Figure 1b) . To understand the mechanism underlying CREB deficiency in JMML, we evaluated the mRNA expression of CREB in MNCs from 31 JMML patients using relative quantitative real-time RT-PCR (qRT-PCR). The median of the relative quantity (RQ) of CREB mRNA from patients was significantly lower than that from 17 normal adults (0.42 vs 1.00, Po0.001, Figure 1c ). This indicates that the regulation of CREB transcription is disrupted in JMML. However, there was no linear correlation between CREB mRNA and CREB protein levels in JMML, suggesting that additional mechanism(s) affecting protein levels may be involved. These results, together with the AML data, 10 suggest that a balanced amount of CREB is critical for maintaining cells with proper responsiveness to GM-CSF in hematopoiesis.
Phosphorylation at Ser-133 of CREB is required for the transcriptional activation of early growth response gene-1 (Egr-1) in response to GM-CSF stimulation in hematopoietic cell lines, but not to IL-3 stimulation. 11 Egr-1 upregulates the PTEN gene. Mice lacking Egr-1 exhibit a significant increase in steady-state levels of dividing hematopoietic stem cells (HSCs) in the BM, and a striking spontaneous mobilization of HSCs into blood. 12 Egr-1 has a deterministic role in governing the development of hematopoietic cells along the macrophage lineage. 13 Therefore, we hypothesized that Egr-1 expression may be deficient in JMML because of the deficient transcriptional activation of CREB. We first evaluated Egr-1 protein levels by western blot in MNCs of 24 patients. We found that 21/24 (87%) of subjects were substantially Egr-1 protein deficient (Figure 1a) . If additional studies confirm our data, Egr-1 would be the most frequent protein deficiency in JMML. Owing to no commercial ELISA assay being available for Egr-1 protein quantification, we were unable to quantitatively evaluate the levels of Egr-1 protein in JMML. Instead, we quantified Egr-1
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